INDEPENDENT NEWS • U.S. & WORLD
New York · ETLos AngelesLondonTokyoSydney
Tuesday, Nov 17, 2026 · ET
NEWS THAT MATTERS.
AS IT UNFOLDS.
World

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Published November 10, 2026 8:00 am • Updated November 10, 2026 8:00 am •
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
Photo via The Guardian World

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but…

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but…

Source: The Guardian World — Original report ↗

WorldLine News is displaying a source-attributed brief. Details may evolve. The linked publication is responsible for its original reporting.

Original source: The Guardian World ↗